全球血小板减少症市场 – 2029 年行业趋势和预测

市场分析和规模

近年来，血小板减少症市场预计在预测期内将快速增长。血小板减少症患者的血液中血小板数量较少。血小板生成效率低、血小板脾脏滞留和血小板降解过快是血小板减少症的主要原因。根据 2014 年《专业医学杂志》上发表的一项名为《血小板减少症频率》的研究，60 岁及以上患有非肝硬化性肝病的人患血小板减少症的频率较高。

Data Bridge Market Research 分析称，2021 年血小板减少症市场价值为 41.4 亿美元，预计到 2029 年将达到 60.2 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 4.79%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

血小板减少症是一种血液中血小板数量异常低的疾病。血小板是由骨髓中较大的细胞产生的血细胞。血小板结合在一起形成一个栓塞来封住伤口。这种堵塞被称为血凝块。因为血凝块也称为血栓，所以血小板也称为血栓细胞。

报告范围和市场细分

Thrombocytopenia Market Dynamics

Drivers

• Increasing prevalence of autoimmune diseases

The rising prevalence of autoimmune diseases is a primary driver of the thrombocytopenia market's growth. Along with this, the increasing incidences of pathological conditions and bleeding disorders will influence the market dynamics during the forecast period.  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of thrombocytopenia market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the thrombocytopenia market. Additionally, high disposable income and increase in the prevalence rate of thrombocytopenia across the globe will result in the expansion of the market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the thrombocytopenia market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the thrombocytopenia market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of thrombocytopenia will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the thrombocytopenia market. Additionally, side effects linked with the treatment and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This thrombocytopenia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thrombocytopenia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

People of various ages, races, and genders can develop thrombocytopenia. Approximately 5% of pregnant women develop moderate thrombocytopenia shortly before giving birth for unknown causes.

Thrombocytopenia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Thrombocytopenia Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of thrombocytopenia in recent months.

Recent Development

• In November 2020, The U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to rilzabrutinib. It is the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor that is used for the treatment of immune thrombocytopenia (ITP). The capacity of Rilzabrutinib to block inflammatory immune cells, abolish autoantibody damaging signalling, and prevent new autoantibody formation without depleting B cells has been demonstrated in studies.

Global Thrombocytopenia Market Scope

The thrombocytopenia market is segmented on the basis of type, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Idiopathic Thrombocytopenic
• Thrombotic Thrombocytopenic
• Drug-induced Thrombocytopenia

On the basis of type, the market is segmented into idiopathic thrombocytopenic, thrombotic thrombocytopenic and drug-induced thrombocytopenia.

Drugs

• Danazol
• Intravenous Immune Globulin
• Rituximab
• Eltrombopag
• Romiplostim
• Splenectomy
• Corticosteroid
• Others

Based on drugs, the market is segmented into danazol, intravenous immune globulin, rituximab, eltrombopag, romiplostim, splenectomy, corticosteroids and others

Route of Administration

• Oral
• Parenteral
• Others

The route of administration segment for the thrombocytopenia market is segmented into oral, parenteral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the thrombocytopenia market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the thrombocytopenia market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Thrombocytopenia Market Regional Analysis/Insights

The Thrombocytopenia market is analysed and market size insights and trends are provided by country, type, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Thrombocytopenia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

北美在血小板减少症市场占据主导地位，因为该地区血小板减少症的患病率不断上升。此外，主要关键参与者对新技术的关注度不断提高，这将进一步推动该地区市场的增长率。

由于人口数量和医疗保健支出的增加，预计亚太地区在预测期内将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和血小板减少症市场份额分析

血小板减少症市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对血小板减少症市场的关注有关。

血小板减少症市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（耶路撒冷）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来公司 (美国)
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• AbbVie Inc.（美国）
• 强生私人有限公司（美国）
• Cipla Inc.（美国）  
• 雅培（美国）
• 默克集团（德国）
• Amneal Pharmaceuticals LLC.（美国）
• 安进公司 (美国)
• 勃林格殷格翰国际有限公司（德国）
• 卫材株式会社（日本）

SKU-53173